Aneela Majeed1, Marti M Larriva2, Ahmad Iftikhar3, Adeela Mushtaq4, Patrick Campbell2, Mustafa Nadeem Malik5, Abdul Rafae5, Muhammad Abu Zar5, Ahmad Kamal5, Midhat Lakhani5, Nageena Rani Khalid5, Tirdad T Zangeneh6, Faiz Anwer5,7. 1. Department of Medicine, Division of Infectious Diseases, Stanford University, Stanford, CA. 2. Department of Pharmacy, University of Arizona, Tucson, AZ. 3. Department of Medicine, University of Arizona, Tucson, AZ. 4. Department of Medicine, University of Pittsburgh Medical Center, McKeesport, PA. 5. Department of Medicine, Division of Hematology and Oncology, University of Arizona, Tucson, AZ 85724. 6. Department of Medicine, Division of Infectious Diseases, University of Arizona, Tucson, AZ. 7. Taussig Cancer Center, Department of Hematology, Medical Oncology, Cleveland Clinic, Cleveland, Ohio 44195.
Abstract
INTRODUCTION: The aim of our study is to evaluate risk factors associated with the development of C. difficile infection (CDI) in hematopoietic stem cell transplant (HSCT) patients, determine its incidence and report outcomes of CDI in our patient population. METHODS: We performed a retrospective review of medical records of adult HSCT recipients diagnosed between 2013 and 2016 at our center. Logistic regression models were used to determine the relationship between risk factors and the odds of CDI. RESULTS: The overall incidence of CDI in HSCT patients was 9.4%. The incidence of CDI was higher in allogeneic HSCT (20%) versus autologous HSCT (4.8%). No statistically significant differences in age, gender, cancer type, transplant type were found between those who developed CDI and those who did not. However, patients with CDI had a longer length of stay (25 days) and used more antibiotics (30 days prior to and during admission for HSCT) than non-CDI patients (19 days). Only two of 17 patients (11.8%) with CDI experienced recurrence among 180 patients after HSCT. No patient suffered from toxic megacolon or ileus and no patient underwent colectomy. There was no mortality associated with CDI at our center. CONCLUSION: CDI has an incidence rate of 9.4% in HSCT recipients. Established risk factors including age, gender, cancer type, and transplant type were not identified as risk factors in our population. However, longer LOS and use of greater than four lines of antibiotics were observed among those with CDI compared to those without CDI.
INTRODUCTION: The aim of our study is to evaluate risk factors associated with the development of C. difficile infection (CDI) in hematopoietic stem cell transplant (HSCT) patients, determine its incidence and report outcomes of CDI in our patient population. METHODS: We performed a retrospective review of medical records of adult HSCT recipients diagnosed between 2013 and 2016 at our center. Logistic regression models were used to determine the relationship between risk factors and the odds of CDI. RESULTS: The overall incidence of CDI in HSCT patients was 9.4%. The incidence of CDI was higher in allogeneic HSCT (20%) versus autologous HSCT (4.8%). No statistically significant differences in age, gender, cancer type, transplant type were found between those who developed CDI and those who did not. However, patients with CDI had a longer length of stay (25 days) and used more antibiotics (30 days prior to and during admission for HSCT) than non-CDI patients (19 days). Only two of 17 patients (11.8%) with CDI experienced recurrence among 180 patients after HSCT. No patient suffered from toxic megacolon or ileus and no patient underwent colectomy. There was no mortality associated with CDI at our center. CONCLUSION: CDI has an incidence rate of 9.4% in HSCT recipients. Established risk factors including age, gender, cancer type, and transplant type were not identified as risk factors in our population. However, longer LOS and use of greater than four lines of antibiotics were observed among those with CDI compared to those without CDI.
Authors: Yeon Joo Lee; Esther S Arguello; Robert R Jenq; Eric Littmann; Grace J Kim; Liza C Miller; Lilan Ling; Cesar Figueroa; Elizabeth Robilotti; Miguel-Angel Perales; Juliet N Barker; Sergio Giralt; Marcel R M van den Brink; Eric G Pamer; Ying Taur Journal: J Infect Dis Date: 2017-04-01 Impact factor: 5.226
Authors: Stavros Sougioultzis; Lorraine Kyne; Denise Drudy; Sarah Keates; Seema Maroo; Charalabos Pothoulakis; Paul J Giannasca; Cynthia K Lee; Michel Warny; Thomas P Monath; Ciarán P Kelly Journal: Gastroenterology Date: 2005-03 Impact factor: 22.682
Authors: L Clifford McDonald; Dale N Gerding; Stuart Johnson; Johan S Bakken; Karen C Carroll; Susan E Coffin; Erik R Dubberke; Kevin W Garey; Carolyn V Gould; Ciaran Kelly; Vivian Loo; Julia Shaklee Sammons; Thomas J Sandora; Mark H Wilcox Journal: Clin Infect Dis Date: 2018-03-19 Impact factor: 9.079
Authors: Tonya L Scardina; Elena Kang Martinez; Neelam Balasubramanian; Mary Fox-Geiman; Scott E Smith; Jorge P Parada Journal: Pharmacotherapy Date: 2017-03-30 Impact factor: 4.705
Authors: Nicole M Boyle; Amalia Magaret; Zach Stednick; Alex Morrison; Susan Butler-Wu; Danielle Zerr; Karin Rogers; Sara Podczervinski; Anqi Cheng; Anna Wald; Steven A Pergam Journal: Antimicrob Resist Infect Control Date: 2015-10-14 Impact factor: 4.887
Authors: Fernanda Spadão; Juliana Gerhardt; Thais Guimarães; Frederico Dulley; João Nóbrega de Almeida Junior; Marjorie Vieira Batista; Maria Aparecida Shikanai-Yasuda; Anna Sara Levin; Silvia Figueiredo Costa Journal: Rev Inst Med Trop Sao Paulo Date: 2014 Jul-Aug Impact factor: 1.846